SpringerProtocols: Abstract: Construction of VNP20009: A Novel, Genetically Stable Antibiotic-Sensitive Strain of Tumor-Targeting Salmonella for Parenteral Administration in Humans

Construction of VNP20009: A Novel, Genetically Stable Antibiotic-Sensitive Strain of Tumor-Targeting Salmonella for Parenteral Administration in Humans

By: Kenneth Brooks Low², Martina Ittensohn³, Xiang Luo³, Li-Mou Zheng³, Ivan King³, John M. Pawelek², David Bermudes³

Abstract

Full Text

Download PDF (218K)

The engineering of tumor-targeting Salmonella strains bearing a high degree of both attenuation and tumor inhibition is a recently developed approach to vector-based treatment of cancer (1,2). Tumor-targeted Salmonella have many desirable features for a tumor-selective delivery vehicle:

Affiliation(s): (2) Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT
(3) Vion Pharmaceuticals, New Haven, CT

Book Title: Suicide Gene Therapy: Methods and Reviews

Series: Methods in Molecular Medicine | Volume: 90 | Pub. Date: Nov-04-2003 | Page Range: 47-59 | DOI: 10.1385/1-59259-429-8:47

Subject: Genetics/Genomics

References

Download References

1.	Pawelek, J., Low, K. B., and Bermudes, D. (1997) Tumor-targeted Salmonella as a novel anticancer agent. Cancer Res. 57, 4537–4544.

2.	Low, K. B., Ittensohn, M., Le, T., et al. (1999) Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nature Biotechnol. 17, 37–41.

3.	Angelakopoulos, H. and Hohmann, E. L. (2000) Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68, 2135–41.

4.	Cryz, S. J. Jr, Que, J. U., Levine, M. M., Wiedermann, G., and Kollaritsch, H. (1995) Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect. Immun. 63, 1336–1339.

5.	Dilts, D. A., Riesenfeld-Orn, I., Fulginiti, J. P., et al. (2000) Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 18, 1473–1484.

6.	Gonzales, C., Hone, D., Noriega, F. R., et al. (1994) Salmonella typhi vaccine strain CVD904 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169, 927–931.

7.	Hohmann, E. L., Oletta, C. A., and Miller, S. I. (1996) Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 14, 19–24.

8.	Hohmann, E. L., Oletta, C. A., Killeen, K. P., and Miller S. I. (1996) phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173, 1408–1414.

9.	Kollaritsch, H., Furer, E., Herzog, C., Wiedermann, G., Que, J. U., and Cryz, S. J., Jr. (1996) Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines. Infect. Immun. 64, 1454–1457.

10.	Levine, M. M., Hone, D. M., Stocker, B. A. D., and Cadoz, M. (1990) New and improved vaccines against typhoid fever, in: New Generation Vaccines, (Woodrow, G. C. and Levine, M. M., eds.), Marcel Dekker, New York, pp. 269–287.

11.	Levine, M. M., Ferreccio, C., Abrego, P., Martin, O. S., Ortiz, E., and Cryz, S. (1999) Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17(Suppl. 2), S22–S27.

12.	Tacket, C. O., Hone, D. M., Curtiss, R., III, et al. (1992) Comparson of the safety and immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 60, 536–541.

13.	Tacket, C. O., Sztein, M. B., Losonsky, G. A., et al. (1997) Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65, 452–456.

14.	Tacket, C. O., Sztein, M. B., Wasserman, S. S., et al. (2000) Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68, 1196–1201.

15.	Clairmont, C., Lee, K. C., Pike, J., et al. (2000) Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J. Infect. Dis. 181, 1996–2002.

16.	Lee, K. C., Zheng, L.-M., Luo, X., et al. (2000) Comparative evaluation of the acute toxic effects in monkeys, pigs, and mice of a genetically engineered Salmonella strain (VNP20009) being developed as an antitumor agent. Int. J. Toxicol. 19, 19–25.

17.	Davis, R. W., Botstein, D., and Roth, J. R. (1980) Advanced Bacterial Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

18.	Bermudes, D., Low, B., and Pawelek, J. (2000) Tumor-targeted Salmonella: strain development and expression of the HSV TK effector gene, in: Gene Therapy: Methods and Protocol, (Walther, W. and Stein U. eds.), Humana, Totowa, NJ, Vol. 35, pp. 419–436.

19.	Bochner, B. R., Huang, H-C., Schieven, G. L., and Ames, B. N. (1980) Positive selection for loss of tetracycline resistace. J. Bacteriol. 143, 926–933.

20.	Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

21.	Russell, C. B., Thaler, D. S., and Dalhlquist, F. W. (1989) Chromosomal transformation of Escherichia coli recD-strains with linearized plasmids. J. Bacteriol. 171, 2609–2613.

22.	Murray, S. R., Bermudes, D., de Felipe, K. S., and Low, K. B. (2001) Extragenic suppressors of ^msbB ⁻ growth defects in Salmonella. J. Bacteriol. 183, 5554–5561.

23.	Donnenberg, M. S. and Kaper, J. B. (1991) Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect. Immun. 59, 4310–4317.

24.	Galán, J. E., Nakayama, K., and Curtiss, R., III. (1990) Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 94, 29–35.

Comments (Loading...)

Post comment/View all comments